Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies for rare diseases, recently announced a successful financing that will allow them to address CMT through its innovative therapeutic candidate, ALE2. According to the company, ALE2 targets mutations in tRNA synthetase genes, several of which are linked to CMT2 subtypes, such as the GARS1 gene in CMT2D.
Alesta Therapeutics is working on a treatment to tackle the nerve damage caused by tRNA synthetase gene mutations in certain types of CMT. According to the company, their therapy, ALE2, works by shutting down a cell stress signal (called GCN2) that stays stuck in the “on” position due to these mutations, leading to ongoing nerve damage. Results in early lab studies with ALE2 are encouraging for CMT.
CMTA shares this exciting update from our CMTA-STAR Alliance Partner as part of our mission to empower the CMT community with the latest research breakthroughs, driving progress, delivering hope, and bringing us closer to effective treatments and a cure.
Register with Patients as Partners in Research Today
CMTA’s Patients as Partners in Research program connects individuals with CMT to groundbreaking studies, like those exploring ALE2 as a potential therapy, should this advance to a clinical trial. By registering today, you ensure you’re among the first to hear about new trials and opportunities to participate in and help accelerate CMT research.
If you’re not yet registered with Patients as Partners in Research, now is the time! Registration is free, secure, and open to everyone with CMT. Signing up today means you’ll be the first to know when new trials are announced, and you’ll always be in the loop with the latest advances in research. Together, we accelerate the research that brings us closer to effective treatments and a cure.
Create Your Patients as Partners in Research Profile
Published on: January 23, 2025